#### **DEPARTMENT OF DEFENSE**

#### GENERAL SERVICES ADMINISTRATION

# NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[OMB Control No. 9000-0114; Docket 2016-0053; Sequence 23]

# Submission for OMB Review; Right of First Refusal of Employment

**AGENCY:** Department of Defense (DOD), General Services Administration (GSA), and National Aeronautics and Space Administration (NASA).

**ACTION:** Notice of request for public comments regarding an extension to an existing OMB clearance.

SUMMARY: Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a previously approved information collection.

**DATES:** Submit comments on or before August 15, 2016.

ADDRESSES: Submit comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: Office of Information and Regulatory Affairs of OMB, Attention: Desk Officer for GSA, Room 10236, NEOB, Washington, DC 20503. Additionally submit a copy to GSA by any of the following methods:

- Regulations.gov: http://
  www.regulations.gov. Submit comments
  via the Federal eRulemaking portal by
  searching the OMB control number.
  Select the link "Submit a Comment"
  that corresponds with "Information
  Collection 9000–0114, Right of First
  Refusal of Employment". Follow the
  instructions provided at the "Submit a
  Comment" screen. Please include your
  name, company name (if any), and
  "Information Collection 9000–0114,
  Right of First Refusal of Employment"
  on your attached document.
- Mail: General Services Administration, Regulatory Secretariat Divison (MVCB), 1800 F Street NW., Washington, DC 20405. ATTN: Ms. Flowers/IC 9000–0114, Right of First Refusal of Employment.

Instructions: Please submit comments only and cite Information Collection 9000–0114, Right of First Refusal of Employment, in all correspondence related to this collection. Comments received generally will be posted without change to http://

www.regulations.gov, including any personal and/or business confidential information provided. To confirm receipt of your comment(s), please check www.regulations.gov, approximately two to three days after submission to verify posting (except allow 30 days for posting of comments submitted by mail).

FOR FURTHER INFORMATION CONTACT: Mr. Michael O. Jackson, Procurement Analyst, Office of Governmentwide Acquisition Policy, GSA, at 202–208–4949 or via email at michaelo.jackson@gsa.gov.

#### SUPPLEMENTARY INFORMATION:

#### A. Purpose

As prescribed in FAR 7.305(c), the clause at FAR 52.207–3, Right of First Refusal of Employment, deals with adversely affected or separated Government employees resulting from the conversion of work from in-house performance to performance by contract. The clause requires the contractor to give these employees an opportunity to work for the contractor who is awarded the contract.

The information gathered will be used by the Government to gain knowledge of which employees, adversely affected or separated as a result of the contract award, have gained employment with the contractor within 90 days after contract performance begins. A notice was published in the **Federal Register** at 81 FR 19606 on April 5, 2016. No comments were received.

### **B.** Annual Reporting Burden

Number of Respondents: 10.
Responses per Respondent: 1.
Total Responses: 10.
Hours per Response: 3.
Total Burden Hours: 30.
Frequency of Collection: On occasion.
Affected Public: Businesses or other for-profit and not-for profit organizations.

Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW., Washington, DC 20405, telephone 202–501–4755. Please cite OMB Control No. 9000–0114, Right of First Refusal of Employment, in all correspondence.

Dated: July 11, 2016.

### Kathlyn Hopkins,

Acting Director, Federal Acquisition Policy Division, Office of Governmentwide Acquisition Policy, Office of Acquisition Policy, Office of Governmentwide Policy. [FR Doc. 2016–16685 Filed 7–13–16; 8:45 am]

BILLING CODE 6820-EP-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Supplemental Evidence and Data for Systematic Reviews Request on Osteoarthritis of the Knee: An Update

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), HHS.

**ACTION:** Request for supplemental evidence and data submissions.

**SUMMARY:** The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Supplemental datasets are being solicited to inform the review of Osteoarthritis of the Knee: An Update. which is currently being conducted by AHRQ's Evidence-based Practice Centers (EPC) Programs. Obtaining access to published and unpublished pertinent scientific information will improve the quality of this review. AHRQ is conducting this systematic review pursuant to section 902(a) of the Public Health Service Act, 42 U.S.C. 299a(a).

**DATES:** Submission Deadline on or before August 15, 2016.

#### ADDRESSES:

Email submissions: SEADS@epc-src.org.

Print submissions:

Mailing Address: Portland VA Research Foundation, Scientific Resource Center, ATTN: SEADS Coordinator, P.O. Box 69539, Portland, OR 97239.

Shipping Address (FedEx, UPS, etc.): Portland VA Research Foundation, Scientific Resource Center, ATTN: SEADS Coordinator, 3710 SW U.S. Veterans Hospital Road, Mail Code: R&D 71, Portland, OR 97239.

### FOR FURTHER INFORMATION CONTACT:

Ryan McKenna, Telephone: 503–220–8262 ext. 51723 or Email: *SEADS@epcsrc.org*.

SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned its Evidence-based Practice Centers (EPC) Programs to complete a review of the evidence a review that updates information on treatments for osteoarthritis of the knee. The review will be titled Osteoarthritis of the Knee: An Update.

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, AHRQ is supplementing the usual manual and electronic database searches of the literature by requesting

information (e.g., details of studies conducted) from the public. We are looking for studies that report on treatments for osteoarthritis of the knee, including those that describe adverse events. The entire research protocol, including the key questions, is also available online at: https://www.effective healthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=2247.

This notice is to notify the public that the EPC program would find the following information on treatments for osteoarthritis of the knee helpful:

- A list of completed studies that your organization has sponsored for this indication. In the list, please *indicate* whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.
- For completed studies that do not have results on ClinicalTrials.gov, please provide a summary, including the following elements: Study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.
- A list of ongoing studies that your organization has sponsored for this indication. In the list, please provide the ClinicalTrials.gov trial number or, if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.
- Description of whether the above studies constitute all Phase II and above clinical trials sponsored by your organization for this indication and an index outlining the relevant information in each submitted file.

Your contribution is very beneficial to the EPC Program. The contents of all submissions will be made available to the public upon request. Materials submitted must be publicly available or could be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC Program.

This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ's EPC program Web site and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: https://effectivehealthcare.ahrq.gov/index.cfm/join-the-email-list1/.

The systematic review will answer the following questions. This information is provided as background. AHRQ is not requesting that the public provide answers to these questions. The entire research protocol, is available online at: https://www.effective healthcare.ahrq.gov/search-for-guidesreviews-and-reports/?pageaction=displayproduct&productID=2247

#### **Key Questions**

Key Question 1

- I. What is the clinical effectiveness of oral glucosamine and/or chondroitin, physical treatments, weight loss, oral serotonin-norepinephrine reuptake inhibitors (SNRIs), intraarticular corticosteroids and/or prolotherapy, topical or transdermal analgesics, acupuncture, or cell-based therapies in patients with primary or secondary OA of the knee, compared with appropriate placebo/sham controls or compared with other active interventions?
- II. How do the outcomes of each intervention differ by the following population and study characteristics: Sex, disease subtype (lateral, patellofemoral), severity (stage/baseline pain and functional status), weight status (body mass index), baseline fitness (activity level), comorbidities, prior or concurrent treatments (including self-initiated therapies), and treatment duration or intensity?

#### Key Question 2

- I. What harms are associated with each intervention in patients with primary or secondary OA of the knee?
- II. How do the harms associated with each intervention differ by the following population or study characteristics: Sex, disease subtype (lateral tibiofemoral, patellofemoral), severity (stage/baseline pain and functional status), weight status (body mass index), baseline fitness (activity level), comorbidities, prior or concurrent treatments (including self-initiated therapies), and treatment duration or intensity?

# PICOTS (Population, Intervention, Comparator, Outcome, Timing, Setting)

Population(s)

- I. Adults (age 18 or over) with a diagnosis of primary (or secondary) OA of the knee, as defined by the American Academy of Orthopaedic Surgeons (AAOS, 2013), ACR clinical classification criteria, or Kellgren-Lawrence stage.
- II. Subpopulations of interest include those defined by sex, disease subtype (e.g., patellofemoral, or medial tibiofemoral), disease severity (stage/pain or functional status), body mass index, fitness/ activity level, prior treatment, concurrent treatment(s), comorbidities

#### III. Exclusions:

- A. Studies of individuals under age 18; those with OA caused by a congenital condition; and those with OA concomitant with a meniscal or anterior cruciate ligament tear will be excluded because these participants have conditions that differ importantly from the vast majority of OA patients
- B. Studies that include those who have had knee replacement surgery on the affected limb or for whom outcomes will be measured after knee replacement surgery or who have concomitant joint disease such as rheumatoid arthritis or gout will be excluded because these conditions or procedures will confound assessment of the outcomes of interventions.
- C. If three or more RCTs of a particular intervention are included that enroll at least 50 participants per study arm, smaller studies of the same intervention will be excluded unless they report on a subgroup analysis of interest because studies on management of OA of the knee that enroll fewer than 50 participants per study arm have been shown to have high risk of bias and significantly larger effect sizes.

#### Interventions

- I. Pharmacologic treatments
  - A. Oral agents
  - i. Glucosamine and/or chondroitin
  - ii. SNRIs (to be assessed for review in next update)
  - B. Intra-articular injected agents (to be assessed for review in next update)
  - i. Corticosteroids (to be assessed for review in next update)
  - ii. Prolotherapeutic agents (e.g. dextrose) (to be reviewed in next update)

- iii. Hyaluronic acid (to be assessed for review in next update)
- C. Topical and transdermal agents (to be assessed for review in next update)
- i. Capsaicin (to be assessed for review in next update)
- ii. NSAIDs (to be assessed for review in next update)
- II. Cell-based therapies
  - A. Platelet-rich plasma
  - B. Intraarticular or arthroscopic administration of mesenchymal stem-cells or chondrocytes or tissue
  - C. Exclusions:
  - Phase I or II trials will not be included for efficacy, as the interventions are generally not FDA-approved for use.
- III. Physical treatments and/or weight loss
  - A. Physical therapy and exercise programs
  - i. Manual therapy
  - ii. Land-based therapy and/or exercise
  - iii. Exercise programs (aerobic, resistance)
  - iv. Aquatherapy
  - v. Balneotherapy, mud therapy
  - vi. Heat or cold
  - vii. Self-management programs
  - B. Weight loss
  - C. Braces or kinesiology taping
  - D. Orthotic shoe inserts and/or wedges
  - E. Vibrating platform
  - F. Neuromuscular electrical stimulation (e.g., Transcutaneous electrical nerve stimulation)
- IV. Acupuncture (to be assessed for review in next update)
  - A. Needle acupuncture alone (to be assessed for review in next update)
  - B. Moxibustion (to be assessed for review in next update)
- V. Combination interventions (to be assessed for review in next update)
  - A. Sequential treatment algorithms (to be assessed for review in next update)

#### **Comparators**

- I. Pharmacologic treatments: Placebocontrolled or head-to-head noninferiority only
- II. Cell-based therapies: Placebo- or sham-controlled only
- III. Physical treatments and/or weight loss: Placebo-controlled, usual carecontrolled, or wait list-controlled only except for weight loss
- IV. Neuromuscular electrical stimulation: Sham stimulation without current
- V. Wait list
- VI. Treatment as usual
- VII. Studies that use the untreated knee as a control will be excluded, based on evidence indicating that

- individuals with OA in one knee are likely to have some, but not necessarily identically, reduced function in the other knee and that treatment of one knee only may improve pain in that knee but may not markedly improve function
- VIII. Studies that use participants as their own controls will be excluded, unless no randomized controlled trials are identified for a particular intervention of interest, as quasiexperimental designs provide weaker evidence.

#### IX. Exclusions:

A. Studies that use an active control that has not been established to be effective will be excluded. Efficacy and effectiveness must be established before examining comparative effectiveness questions.

#### Outcomes

- I. Short-term clinical outcomes
  - A. Pain (e.g., VAS, WOMAC, KOOS,)
  - B. Joint stiffness (WOMAC)
  - C. Function (WOMAC, Lequesne, others)
  - D. OARSI physical outcomes (e.g., timed up-and-go, 6-minute walk test)
  - E. Patient Reported Outcome Measurement System (PROMIS®) and Osteoarthritis-Computer Adaptive Test (OA–CAT)
  - F. Inflammation or effusion
  - G. Medication use
- II. Long-term clinical outcomes
  A. Any of the short-term clinical
  - outcomes B. Instrumental activities of daily
  - living (IADLs)
    C. Quality of life (e.g., SF-36,
    EuroQual EQ-5D, Arthritis Self
  - EuroQuol EQ-5D, Arthritis Self-Efficacy scale, global assessment, patient satisfaction)
  - D. Surgery (*i.e.*, rate of undergoing knee replacement)
- III. Adverse effects of intervention(s)
- IV. Outcome reporting
  - A. Only studies that report outcomes for knee OA alone
  - B. Mean differences at followup or percent of responders at followup will be abstracted

#### **Timing**

Minimum 1 month follow-up from initiation of treatment

### Settings

Any setting

#### Andrew B. Bindman,

 $AHRQ\,Director.$ 

[FR Doc. 2016–16632 Filed 7–13–16; 8:45 am]

BILLING CODE 4160-90-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

### National Institute for Occupational Safety and Health (NIOSH), Safety and Occupational Health Study Section: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92–463) of October 6, 1972, that the Safety and Occupational Health Study Section, Centers for Disease Control and Prevention, Department of Health and Human Services, has been renewed for a 2-year period through June 30, 2018.

For more information contact: JoAnne Fairbanks, Executive Secretary, Safety and Occupational Health Study Section, Department of Health and Human Services, 1600 Clifton Road NE., Mailstop E74, Atlanta, Georgia 30333, telephone 304/285–6143 or fax 304/285–6147.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Catherine Ramadei,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention

[FR Doc. 2016–16583 Filed 7–13–16; 8:45 am]

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

### National Institute for Occupational Safety and Health (NIOSH), Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), and pursuant to the requirements of 42 CFR 83.15(a), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

Times and Dates: 8:15 a.m.–5:00 p.m., Mountain Time, August 9, 2016; 8:15 a.m.–1:00 p.m., Mountain Time, August 10, 2016.

Public Comment Time and Date: 5:00 p.m.-6:00 p.m.\*, Mountain Time, August 9, 2016.